




FIG. 1




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7




FIG. 8A





FIG. 8B






FIG. 10






FIG. 11



**FIG. 12**

- anti-CD70 CAR
- anti-CD70 CAR + TGF β 1
- ADI-270
- ADI-270 + TGF β 1
- ▲— Target Alone
- △— Target Alone+TGFB1




FIG. 13




FIG. 14




FIG. 15






FIG. 17A

- ◆ Group A: Tumor alone
- ◆ Group B: Donor 1 ADI-270
- ◆ Group C: Donor 1 anti-CD70 CAR
- ◆ Group D: Donor 2 ADI-270
- ◆ Group E: Donor 2 anti-CD70 CAR
- ◆ Group F: Donor 3 ADI-270
- ◆ Group G: Donor 3 anti-CD70 CAR
- ◆ Group H: Donor 1 Untransduced V51

FIG. 17B
Day 40 post-treatment



One-way ANOVA Tukey's multiple comparison test
(Only significant comparisons vs. tumor alone listed)

- ◆ Group A: Tumor alone
- Group B: Donor 1 ADI-270
- ★ Group C: Donor 1 anti-CD70 CAR
- ✦ Group D: Donor 2 ADI-270
- ✦ Group E: Donor 2 anti-CD70 CAR
- ✦ Group F: Donor 3 ADI-270
- ✦ Group G: Donor 3 anti-CD70 CAR
- ✦ Group H: Donor 1 Untransduced Vδ1


FIG. 18A

FIG. 18B






FIG. 19A



- ◆ Group A: Tumor alone + IL-2
- Group B: Tumor alone (no IL-2)
- ▲ Group C: ADI-270 5e6 + IL-2
- ▼ Group D: ADI-270 5e6 (no IL-2)
- ◆ Group E: ADI-270 10e6 + IL-2

FIG. 19B




FIG. 20B





FIG. 20C







FIG. 21






FIG. 22




FIG. 23B

FIG. 23A




FIG. 23D




FIG. 23C




FIG. 24




FIG. 25




FIG. 26A





FIG. 26B

**FIG. 27A**

In vitro repetitive stimulation assay




FIG. 27B

PC3-PSMA targets
Prostate adenocarcinoma




FIG. 28A

In vitro repetitive stimulation assay




FIG. 28B




FIG. 29A




FIG. 29B